Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and Ivermectin in Hospitalized Non-Critical COVID-19 Patients
NCT04391127Phase 3Completed
- Sponsor
- Centenario Hospital Miguel Hidalgo
- Start
- May 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydroxychloroquine and CHILD-IVITAB in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Centenario Hospital Miguel Hidalgo. Primary endpoints: Mean days of hospital stay at 3 months, Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead at 3 months and 1 more. Started May 2020; status: completed.
02
Drugs
hydroxychloroquineCHILD-IVITAB
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04391127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04391127.